Paroxetine and Irritable Bowel Syndrome

Kirsch, Michael A.; Louie, Alan K.

doi:10.1176/appi.ajp.157.9.1523-a

Cited by 17 publications

(6 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Physicians who evaluate patients with IBS symptoms should obtain childhood abuse history as a part of their routine evaluation. As previous reports suggested that SSRIs such as paroxetine may play a beneficial role in the treatment of IBS (14, 15, 17, 37, 55–57), our data suggest that a history of abuse should not be a barrier to prescribing antidepressants for IBS patients. It should also be noted that no antidepressant including paroxetine CR is FDA approved for the treatment of IBS.…”

Section: Discussionsupporting

confidence: 66%

Childhood abuse and treatment response in patients with irritable bowel syndrome: apost-hocanalysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release

Han

Masand

Krulewicz

et al. 2009

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 66%

Childhood abuse and treatment response in patients with irritable bowel syndrome: apost-hocanalysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release

Han

Masand

Krulewicz

et al. 2009

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

“…Several case reports suggested that SSRIs such as paroxetine and fluvoxamine may alleviate IBS symptoms (65–68), although worsening of IBS symptoms after treatment of sertraline was also reported (69). Open‐label investigations have supported a role for SSRIs in IBS.…”

Section: Ssris For Treatment Of Ibsmentioning

confidence: 99%

Irritable bowel syndrome in psychiatric perspectives: a comprehensive review

Pae

Masand

Ajwani

et al. 2007

International Journal of Clinical Practice

View full text Add to dashboard Cite

We comprehensively reviewed the irritable bowel syndrome (IBS) in terms of pathogenesis, psychiatric implications, general management and appropriate role of antidepressants, in particular selective serotonin uptake inhibitors (SSRIs) in the treatment of IBS. English language papers cited in MEDLINE and PychInfo from January 2000 to July 2006 were searched with a combination of the following key words: irritable bowel syndrome, 5-HT, pathogenesis, comorbid, psychiatry, treatment, psychotropic drugs, antidepressant, selective serotonin reuptake inhibitors (fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram and sertraline), tricyclic antidepressants, review, meta-analysis and placebo. The papers on IBS describing the clinical features, pathophysiology, evaluation, management, and clinical trials [randomised placebo-controlled trial (RCT), open-label study or case report] were selected for this review. Further literatures were also detected from references of the identified papers. The epidemiology, diagnostic criteria, pathophysiology, general management, bidirectional comorbidity, summary of currently available RCTs and open-label studies investigating antidepressant efficacy (focusing on SSRIs), and suggestions for SSRI use in IBS were relevantly synthesised based on through review of identified data. This article summarised an up-to-date clinical overview of IBS in psychiatric perspectives as well as to position a current role of SSRIs in the treatment of IBS. From this review, the routine use of SSRIs for IBS treatment cannot be conclusive due to a paucity of RCTs, although a handful of RCTs suggested a potentially beneficial effect of SSRIs over placebo.

show abstract

“…This may be the reason why some of these diverse syndromes respond to antidepressants in general. In this context, paroxetine and other serotonin selective uptake inhibitors (SSRIs) have been successfully used for the treatment of tinnitus, 18,19 irritable bowel syndrome, [20][21][22] burning mouth syndrome, 22 interstitial cystitis 19 and fibromyalgia. 23,24 Again, the common factor for all these syndromes is the absence of peripheral nociception.…”

Section: Discussionmentioning

confidence: 99%

What has dry cough in common with pruritus? treatment of dry cough with paroxetine

Żylicz

Krajnik

2004

Journal of Pain and Symptom Management

View full text Add to dashboard Cite

Distressing persistent dry cough is commonly the consequence of sensitization of the cough reflex. A slight and transient peripheral nociceptive impulse, such as bronchitis, may be perpetuated for weeks because of sensitization of the cough reflex. Cough usually can be inhibited by opioids, but some types of cough can be out of opioid control or even be induced by opioids. We describe here a series of 5 patients with dry cough that did not respond to codeine. Because two of these patients also suffered with pruritus, paroxetine was tried. In all patients, cough ceased within hours to days. The only observed adverse effect was sleepiness in the first days of therapy. Paroxetine should be investigated as antitussive in cases of opioid-resistant cough. The putative mechanism of action of paroxetine on pruritus and rough is discussed.

show abstract

Paroxetine and Irritable Bowel Syndrome

Cited by 17 publications

References 4 publications

Childhood abuse and treatment response in patients with irritable bowel syndrome: apost-hocanalysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release

Childhood abuse and treatment response in patients with irritable bowel syndrome: apost-hocanalysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release

Irritable bowel syndrome in psychiatric perspectives: a comprehensive review

What has dry cough in common with pruritus? treatment of dry cough with paroxetine

Contact Info

Product

Resources

About